Madrigal Pharmaceuticals, Inc.
MDGL
$425.85
-$9.77-2.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 48.70% | -170.07% | 42.27% | -23.26% | 44.45% |
| Total Depreciation and Amortization | 1.62% | 341.90% | -0.69% | 19.83% | 21.81% |
| Total Amortization of Deferred Charges | 42.25% | -11.32% | -14.91% | -9.54% | 0.42% |
| Total Other Non-Cash Items | -12.28% | 9.96% | 24.70% | 18.03% | 1.69% |
| Change in Net Operating Assets | -162.83% | 614.92% | 15.43% | 41.15% | -392.48% |
| Cash from Operations | -267.14% | 269.71% | 47.07% | 14.93% | -55.99% |
| Capital Expenditure | 145.51% | -- | -- | -- | 74.97% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 113.19% | -530.73% | -70.80% | 443.16% | 76.31% |
| Cash from Investing | 113.32% | -532.52% | -70.80% | 441.77% | 76.31% |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -- | -- | -- | -- |
| Issuance of Common Stock | -43.96% | 918.67% | -79.85% | -56.30% | 164.96% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 89.57% | -- | -- | -- | -- |
| Cash from Financing | -96.22% | 13,492.59% | -79.85% | -56.30% | 164.96% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.50% | 4,199.21% | -96.95% | 163.04% | 49.35% |